Northview is a strategic investment and consulting firm focused on the life sciences.
About Our Expertise
Our group consists of former investment bankers and biotech executives who have extensive experience around capital markets, finance strategy, business development planning and execution. We bring real-world practicality grounded in transactional experience to guide our client’s business development activities.
Strategic Life Science Focus
Our group has in-depth knowledge across a wide range of therapeutic areas and product types, with experience in all stages of product development – from discovery to product launches and life-cycle management.
Driven by End-User Insight
Our goal is to help our clients understand the economic value of their technology. To this end, we conduct in-depth clinician, reimbursement and end-user analyses to develop detailed clinical and commercial assessments for our clients.
Our ongoing experience with new technologies, and strong relationships with KOLs in the scientific and engineering community, allows our team to add tremendous value to our companies. We guide the strategic development of technologies for sound patent claims and strong regulatory positions.
Our team combines end-user insight with commercial expertise to develop and advance growth strategies for our clients.
Doug brings over 20 years of experience in life sciences with leadership experience in corporate finance, business development, and management. Over his 9 year tenure at Cardiome Pharma Doug held a series of positions including CFO, President and CBO, and President and CEO. During this time he raised over $300 million from investors and completed over $1 billion in licensing deals. Prior to Cardiome, Doug was an investment banker with Cormark Securities, acting as Managing Director of Life Sciences and has completed over $1B in equity financing for Canadian biotech companies. Doug is currently Chairman and CEO of Aequus Pharmaceuticals, Chairman of Resolution Diagnostics, and serves as a Director for Neovasc, Ico Therapeutics, Synaptive Medical, Alabaster, and Perimeter Medical Imaging. Doug remains a prominent figure in the BC and Canadian biotechnology community with previous positions of Chair of LifeSciences BC and Director with Biotech Canada.